Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™ (6-month paliperidone.
The Pharma Data
SEPTEMBER 1, 2021
Approval is backed by nearly two decades of proven efficacy and safety of Janssen’s long-acting injectable portfolio of schizophrenia medicines. The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. About the Clinical Trial. Results found that 92.5 1 The most common adverse reactions (?5%)
Let's personalize your content